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Breast cancer is the most common cancer diagnosed in women globally, and 5-year net sur-
vival probabilities in high-income countries are generally >80%. A cancer diagnosis and
treatment are often traumatic events, and many women struggle to cope during this period.
Less is known, however, about the long-term mental health impact of the disease, despite
many women living several years beyond their breast cancer and mental health being a
major source of disability in modern societies. The objective of this study was to quantify the
risk of several adverse mental health–related outcomes in women with a history of breast
cancer followed in primary care in the United Kingdom National Health Service, compared
to similar women who never had cancer.
Methods and findings
We conducted a matched cohort study using data routinely collected in primary care across
the UK to quantify associations between breast cancer history and depression, anxiety, and
other mental health–related outcomes. All women with incident breast cancer in the Clinical
Practice Research Datalink (CPRD) GOLD primary care database between 1988 and 2018
(N = 57,571, mean = 62 ± 14 years) were matched 1:4 to women with no prior cancer (N =
230,067) based on age, primary care practice, and eligibility of the data for linkage to hospi-
tal data sources. Cox models were used to estimate associations between breast cancer
survivorship and each mental health–related outcome, further adjusting for diabetes, body
mass index (BMI), and smoking and drinking status at baseline. Breast cancer survivorship
was positively associated with anxiety (adjusted hazard ratio (HR) = 1.33; 95% confidence
interval (CI): 1.29–1.36; p < 0.001), depression (1.35; 1.32–1.38; p < 0.001), sexual dysfunc-
tion (1.27; 1.17–1.38; p < 0.001), and sleep disorder (1.68; 1.63–1.73; p < 0.001), but not
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with cognitive dysfunction (1.00; 0.97–1.04; p = 0.88). Positive associations were also found
for fatigue (HR = 1.28; 1.25–1.31; p < 0.001), pain (1.22; 1.20–1.24; p < 0.001), receipt of
opioid analgesics (1.86; 1.83–1.90; p < 0.001), and fatal and nonfatal self-harm (1.15; 0.97–
1.36; p = 0.11), but CI was wide, and the relationship was not statistically significant for the
latter. HRs for anxiety and depression decreased over time (p-interaction <0.001), but
increased risks persisted for 2 and 4 years, respectively, after cancer diagnosis. Increased
levels of pain and sleep disorder persisted for 10 years. Younger age was associated with
larger HRs for depression, cognitive dysfunction, pain, opioid analgesics use, and sleep dis-
orders (p-interaction <0.001 in each case). Limitations of the study include the potential for
residual confounding by lifestyle factors and detection bias due to cancer survivors having
greater healthcare contact.
Conclusions
In this study, we observed that compared to women with no prior cancer, breast cancer sur-
vivors had higher risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue,
receipt of opioid analgesics, and pain. Relative risks estimates tended to decrease over
time, but anxiety and depression were significantly increased for 2 and 4 years after breast
cancer diagnosis, respectively, while associations for fatigue, pain, and sleep disorders
were elevated for at least 5–10 years after diagnosis. Early diagnosis and increased aware-
ness among patients, healthcare professionals, and policy makers are likely to be important
to mitigate the impacts of these raised risks.
Author summary
Why was this study done?
• More than 570,000 women are carrying on with their lives after having been diagnosed
and treated for breast cancer in the UK. This number is expected to increase.
• Many women feel anxious and/or depressed while undergoing the cancer treatments,
but it is less clear how their mental health fares in the longer term. The evaluation of the
long-term mental health of these women is important to understand what their needs
are and plan health services that are able to mitigate the long-term consequences of
cancer.
• We aimed to estimate the risk of a range of mental health–related outcomes in a popula-
tion-based sample of breast cancer survivors in the UK, compared to women with no
prior cancer.
What did the researchers do and find?
• This study compared the risk of several adverse mental health–related outcomes in
57,571 women with history of breast cancer and 230,067 women with no history of can-
cer followed in primary care in the UK.
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• The results suggest that breast cancer survivorship is associated with raised risks of anxi-
ety, depression, fatigue, sleep disorders, pain, and sexual dysfunction, persisting well
into the survivorship period.
What do these findings mean?
• Breast cancer survivorship is associated with raised risk of several adverse mental
health–related outcomes. For all outcomes, the risk was particularly increased around
diagnosis and during the period of the main treatments for breast cancer.
• Early diagnosis and management of these conditions is likely to be key to mitigate the
impact on the long-term health of cancer survivors.
• Future studies might investigate whether screening breast cancer patients for mental
disorders during this period could help identify patients struggling to cope and enable
interventions to help reduce the long-term burden of the disease.
Introduction
Large numbers of women around the world are currently living beyond a breast cancer diag-
nosis, including over 2.9 million in the United States and 570,000 in the UK, with numbers
projected to rise further [1,2]. Women with a history of breast cancer may experience long-
term physical consequences of treatment, worries about cancer recurrence, employment or
financial difficulties, and other challenges, with potential negative consequences for broader
mental health [3,4]. However, little evidence is available from large-scale population-based
studies to quantify the impact of a history of cancer on long-term mental health.
In a recent systematic review [5], anxiety and depression were found to be more common
in breast cancer survivors than in women with no cancer history, but, evidence was often
drawn from studies at high risk of selection and information bias, likely to be confounded by
age and socioeconomic status, and lacking generalisability. Only a few population-based stud-
ies have been done, finding conflicting effect sizes, with relative risks of clinically diagnosed
depression or anxiety ranging from no association to a doubling of risk in cancer survivors [5–
7]. Increased risks of other mental health outcomes including suicide and neurocognitive and
sexual dysfunctions have also been observed; existing evidence on sleep disturbance is insuffi-
cient to draw conclusions [5]. The overall burden of mental health disorders is remarkably
high, particularly in high-income settings [8], and the efficient planning and delivery of cancer
support and mental health services that suit the needs of the largest group of cancer survivors
in the population requires timely and robust estimates on the risk of clinically assessed out-
comes at population level.
We therefore aimed to quantify the associations between breast cancer history and the pri-
mary outcomes of anxiety and depression and the secondary outcomes of cognitive dysfunc-
tion, fatigue, sleep disorder, sexual dysfunction, fatal and nonfatal self-harm, pain, and opioid
analgesics prescription using population-based electronic health records data from UK pri-
mary care. Pain and fatigue were included due to their likely links with both cancer history
and mental health.
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Methods
Ethics statement
This study was conducted following a priori defined methods and is reported as per the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline
(S1 Checklist).
The study protocol was approved by the Independent Scientific Advisory Committee
(ISAC) at the Medicines and Healthcare products Regulatory Agency (S1 Protocol, ref 18_253)
and received favourable ethical opinion from the Research Ethics Committee at the London
School of Hygiene and Tropical Medicine (ref 16225). Individual participant consent is not
required.
Study design and data sources
We conducted a matched cohort study using data from the UK Clinical Practice Research
Datalink (CPRD) GOLD primary care database (July 2018 version), which contains anon-
ymised electronic health records data from 761 general practitioners’ (GPs) practices in
England, Wales, Northern Ireland, and Scotland [9] and is broadly representative of the UK
population in terms of age, sex, and ethnicity [10]. All patients were assigned a measure of rela-
tive deprivation (proxy for socioeconomic status) based on their GP practice postcode Index
of Multiple Deprivation (IMD) [11–14].
Approximately 75% of the GP practices in England consent to have their data linked to
other sources of data (linkage is not allowed for other UK jurisdictions). For eligible patients,
the patient-level primary care data were linked, using deterministic methods [15], to the Office
for National Statistics (ONS) mortality data [16], the Hospital Episodes Statistics–Admitted
Patient Care (HES-APC) database [17], and the patient postcode level of IMD [11]. Linked
ONS mortality data were used to identify cases of suicide; HES-APC data were used to define
self-harm and improve outcome ascertainment in sensitivity analyses.
Study populations
The exposed cohort included all women (�18 years) with an incident diagnosis of breast can-
cer (not including in situ tumours; code list available in Table A in S1 Codelists) recorded in
their primary care record between database inception (1987) and July 2018. To ensure breast
cancer diagnoses were incident, we required 12 months of follow-up in CPRD prior to the
diagnosis. We excluded women with severe mental or neurological disorders (i.e., schizophre-
nia and other psychotic disorders, bipolar disorders, neurocognitive disorders, and substance-
related disorders) or another cancer diagnosis (except nonmelanoma skin cancer) prior to
breast cancer. To ensure that all mental health–related outcome events were incident, we
excluded from each outcome-specific analysis patients who had evidence of that outcome in
the year before the breast cancer diagnosis (index date). Patients with an outcome last recorded
>1 year before the breast cancer diagnosis were not excluded, and the condition was assumed
to be in remission.
For each breast cancer survivor, we randomly selected 4 control women with no history of
cancer (except nonmelanoma skin cancer) at the index date (date of diagnosis), matched to
the cancer survivor on age (within a 3-year range), primary care practice, and eligibility of the
data for hospital data linkage (to enable a sensitivity analyses among patients with linked data).
Ethnicity was missing for approximately 60% of women and not included in the matching pro-
cess. Women in the exposed cohort were eligible for selection as controls up to the date of
breast cancer diagnosis. Similar to the exposed group, women in the unexposed cohort had
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�12 months of uninterrupted prior registration before the index date (date of breast cancer
diagnosis of the matched case). Exclusion criteria were as for the exposed.
Outcomes
The primary outcomes were anxiety and depression. Anxiety included generalised anxiety dis-
order, panic disorder, social anxiety, agoraphobia, obsessive–compulsive disorders, and stress-
related disorders with anxiety (see S1 Methods for more details). Depression included major
depressive disorder, dysthymia, and stress-related disorders with depressed mood. Mixed anx-
iety and depression was included in both definitions. Outcomes were identified by either a
diagnostic Read code for the conditions named above, or a Read code for a symptom (e.g., low
mood) accompanied by a prescription within 90 days for an antidepressant, for depression, or
an anxiolytic or relevant antidepressant, for anxiety (S1 Methods). The Read code lists (Tables
B–P in S1 Codelists) were informed by a systematic review on the topic [15] and revised by a
practicing GP (author GF).
Secondary outcomes were cognitive dysfunction, sleep disorder, sexual dysfunction, fatal
and nonfatal self-harm, fatigue, pain, and opioid analgesics prescription. Detailed definitions
are provided in S1 Methods. Briefly, cognitive dysfunction was identified as a Read code for
cognitive impairment, including dementia, or a dementia-specific drug prescription. Sleep dis-
order was defined as a Read code for diagnosis, or a combination of symptoms codes and pre-
scriptions of anxiolytics/hypnotics within 90 days. Fatigue, sexual dysfunction, and pain were
defined using Read codes alone. Prescriptions of opioid analgesics were identified from pri-
mary care prescription data. Fatal and nonfatal self-harm was ascertained using a validated list
of Read codes [18], updated for this study. Suicide was ascertained from linked official death
registration data and was defined by the International Statistical Classification of Diseases and
Related Health Problems 10th Revision (ICD-10) codes X60-X84 and Y10-34, excluding Y33.9
(verdict pending). All Read codelists are provided in Tables B–P in S1 Codelists.
Covariates
Diabetes mellitus, body mass index (BMI), and alcohol and smoking status, all measured at (or
near) the index date, were considered as potential confounders (definitions in S1 Methods).
Deprivation and cardiovascular morbidity were studied as potential effect modifiers.
Statistical analysis
The analysis plan was defined prior to the start of the study and is available in S1 Protocol.
Incidence rates were calculated separately for each outcome in each cohort. Follow-up started
at the index date (date of cancer diagnosis in the exposed cohort; unexposed patient took the
same index date as their matched case) and terminated at the earliest of mental health–related
outcome observed, cancer diagnosis other than breast in the exposed cohort, any cancer diag-
nosis in the comparison cohort, death, transference out of the practice, and last data collection
for the practice.
The association between breast cancer survivorship and each mental health–related out-
come was quantified using Cox regression models (per outcome), with time since index as the
underlying timescale, and stratified on matched set to account for matching. Stratification of
the baseline hazard is a valid way of handling multicentre and matched data if the clustering is
of no intrinsic interest [19,20]. Hospitalisations data are considered the gold standard for cap-
turing self-harm [21], and thus all analyses of fatal and nonfatal self-harm were restricted to
individuals with linked HES data. Hazard ratios (HR) adjusted for diabetes mellitus at baseline
(yes/no), BMI (restricted cubic spline), smoking status (nonsmoker, current smoker, and
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former smoker) and drinking status (never drinker, current drinker, and former drinker),
were estimated for all outcomes in complete cases analyses; multiple imputation was not used,
as the missingness was considered likely to be missing not at random in a primary care setting
[22,23], and complete case analysis minimises bias in this situation, providing missingness is
conditionally independent of the outcome [24]. In the protocol, we planned to include BMI as
categorical covariate; following peer-review comments, the final models included BMI as a
continuous variable modelled using restricted cubic splines. The probability of type I error was
set to 5%; all tests were 2-sided. Robust standard errors were used to calculate 95% confidence
intervals (CIs).
We assessed the potential for effect modification by age group at index date (18 to 34; 35 to
44; 45 to 54; 55 to 64; 65 to 74; 75 to 84;�85 years), practice postcode-linked quintile of IMD,
calendar period of index date (1988 to 1994; 1995 to 1999; 2000 to 2004; 2005 to 2009; 2010 to
2014; 2015 to 2018), follow-up time (1-year interval up to 5 years, 5 to 10 years, and>10 years,
an implicit test of proportional hazards), cardiovascular comorbidity (yes/no), and history of
the mental health–related outcome <1 year before index date (yes/no), by fitting interaction
terms between the exposure and these variables.
Sensitivity analysis
We carried out several sensitivity analyses. For each mental health–related outcome, we
repeated the analysis excluding patients with lifetime history of the outcome before the index
date. To account for the potential that breast cancer survivors may have more contact with
health services, we ran a sensitivity analysis including only patients that had a consultation
with their GP in the year before the index date. For the subset of patients for whom linked data
were available (i.e., approximately 50% of the patients in England), we ran analyses using
linked HES-APC data to improve outcome ascertainment and with adjustment for patient-
(rather than practice-) level IMD. For anxiety, depression, and sleep disorders, we ran analyses
with definitions that are expected to have high specificity, to assess the impact of the code list
in our results. For opioid analgesics, we reran the analysis excluding codeine, which can be
prescribed for its antitussive or antidiarrheal properties. For fatal and nonfatal self-harm, we
ran analyses separately for self-harm and completed suicide.
Results
A total of 57,571 women with history of breast cancer and 230,067 women with no history of
cancer were included in the study (Fig 1). Approximately 20% of all participants had anxiety
recorded>1 year before the index date (date of cancer diagnosis in the exposed group; con-
trols took the same date as matched case), and 29% had history of depression (Table 1). Overall
median follow-up time was 4.5 years in the exposed group (interquartile range (IQR): 1.9 to
8.5 years) and 5.2 years in the comparison group (IQR: 2.2 to 9.3 years). Moreover, 11,790
breast cancer survivors (24%) and 55,609 women in the comparison group (20%) had�10
years of follow-up. Mental health–related outcome-specific follow-up time and person-time at
risk are included in S1A–S1C Table.
Table 2 shows the minimally adjusted (matching factors) and fully adjusted (for diabetes,
smoking, drinking, and BMI) associations between breast cancer survivorship and each
adverse mental health outcome. Minimally adjusted and fully adjusted associations were very
similar. Compared with cancer-free controls, breast cancer survivorship was positively associ-
ated with the primary outcomes of anxiety (fully adjusted HR = 1.33, 95% CI: 1.29 to 1.36,
p< 0.001) and depression (1.35, 1.32 to 1.38, p< 0.001), as well as the secondary outcomes of
sexual dysfunction (1.27; 1.17 to 1.38; p< 0.001), sleep disorder (1.68; 1.63 to 1.73; p< 0.001),
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fatigue (1.28; 1.25 to 1.31; p< 0.001), pain (1.22; 1.20 to 1.24; p< 0.001), receipt of opioid anal-
gesics(1.86; 1.83 to 1.90; p< 0.001), and fatal and nonfatal self-harm (1.15; 0.97 to 1.36,
p = 0.11), although the CI was wide for the latter. There was no statistical evidence of an associ-
ation for cognitive dysfunction (1.00; 0.97 to 1.04, p = 0.88). The full models are presented in
Tables A and B in S2 Table. At 10 years of follow-up, the outcomes with highest cumulative
incidence were pain (breast cancer survivors 85.6%; controls 79.1%), opioid analgesics (breast
cancer survivors 45.5%; controls: 31.1%), depression (breast cancer survivors 28.5%; controls
24.0%), and fatigue (breast cancer survivors 23.9%; controls 19.9%) (Fig 2, S3 Table).
Fig 3 shows results stratified by potential effect modifiers. We found strong statistical evi-
dence supporting interactions between age and the relative risk of depression, cognitive dys-
function, pain, opioid analgesics prescribing, and sleep disorder, with HRs larger for younger
women (for depression: HR = 1.86 [1.69 to 2.04] in women age 18 to 34, falling to 1.28 [1.15 to
1.42] in those 75 to 84, p-interaction <0.001). Women with breast cancer living in the less
deprived areas had higher risks for anxiety, sleep disorders, and opioid analgesic use (for anxi-
ety: HR = 1.39 [1.33 to 1.46] in the least deprived areas, falling to 1.24 [1.19 to 1.30] in the most
deprived areas, p-interaction <0.001). HRs also varied by survivorship time, with the largest
risks around diagnosis that tended to decline over time: In the first year of diagnosis, HRs for
anxiety and depression were 2.10 (2.05 to 2.15) and 1.79 (1.75 to 1.83), and these outcomes
reached similar levels to those of women with no cancer history by the third and fifth year after
diagnosis respectively (p-interaction <0.001 for both outcomes). Finally, there was some varia-
tion by calendar period, with HRs for anxiety, fatigue, sleep disorders, and opioid prescription
largest in the latest period, while the HR for pain was smaller later in calendar time.
Sensitivity analyses
Results of sensitivity analyses are shown in Fig 4. Restricting the analysis to patients with no
prior history of the outcome, or to patients who had been in contact with the GP practice in
Fig 1. Flowchart of the selection of the cohorts used in analyses. CPRD, Clinical Practice Research Datalink; EHR,
electronic health record. �Women with research quality follow-up, as defined by CPRD based on systematic checks for
data quality at both patient and practice level. †Almost all had a first record of breast cancer a few days after the
recorded date of death.
https://doi.org/10.1371/journal.pmed.1003504.g001
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Table 1. Characteristics of the study participants (1988–2018)�.
Women with history of breast cancer Women with no history of cancer
No. % No. %
All participants 57,571 100.00 230,067 100.00
Sociodemographic
Age group at index date (years)†
18–34 781 1.36 3,125 1.36
35–44 4,768 8.28 19,059 8.28
45–54 13,039 22.5 52,114 22.65
55–64 14,436 25.08 57,707 25.08
65–74 12,361 21.47 49,395 21.47
75–84 8,386 14.57 33,524 14.57
85+ 3,800 6.60 15,143 6.58
Calendar period of index date‡
1988–1994 2,656 4.61 10,619 4.62
1995–1999 4,796 8.33 19,149 8.32
2000–2004 11,590 20.13 46,302 20.13
2005–2009 16,381 28.45 65,480 28.46
2010–2014 15,733 27.33 62,862 27.32
2015–2018 6,415 11.14 25,655 11.15
Ethnicity
White 21,187 36.80 86,187 37.46
South Asian 411 0.71 2,247 0.98
Black 271 0.47 1,384 0.60
Other and mixed 221 0.38 1,228 0.53
Unknown 35,481 61.63 139,021 60.43
Practice postcode quintile of IMD
1 (least deprived) 11,381 19.78 45,502 19.78
2 9,913 17.22 39,618 17.22
3 11,820 20.53 47,239 20.53
4 11,736 20.38 46,899 20.39
5 (most deprived) 12,721 22.08 50,809 22.10
Lifestyle
BMI (kg/m2) at index date
<18.50 908 1.58 4,561 1.98
18.50–24.99 20,958 36.40 85,030 36.96
25.00–29.99 17,565 30.51 69,052 30.01
30.00–34.99 8,666 15.05 32,401 14.08
35.00–39.99 3,302 5.74 12,549 5.45
�40.00 1,490 2.59 6,350 2.76
Unknown 4,682 8.13 20,124 8.75
Alcohol intake at index date
Never drinker 7,780 13.51 35,065 15.24
Current drinker 40,438 70.24 156,604 68.07
Former drinker 4,436 7.71 17,181 7.47
Unknown 4,917 8.54 21,217 9.22
Smoking status at index date
Nonsmoker 30,452 52.89 122,985 53.46
Current smoker 9,565 16.61 39,986 17.38
(Continued)
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the year prior the index date, yielded similar results to those of the main analysis. Sensitivity
analyses adjusting for patient-level IMD did not change the results meaningfully. Analyses
where hospital data were also used to identify outcomes resulted in similar risk estimates, as did
the analyses excluding drugs from the definition of outcomes. A sensitivity analysis using only
very specific codes for diagnoses of depressive disorders (e.g., major depressive disorder)
yielded similar results; however, no association was observed when specific codes were used for
anxiety disorders (e.g., generalised anxiety disorder) (HR = 1.02, 95% CI: 0.92 to 1.13, p = 0.69).
Discussion
We found that breast cancer survivorship was associated with our primary outcomes of anxiety
and depression in breast cancer survivors in the UK, compared to women with no prior can-
cer, as well as increased frequency of sleep disorder, sexual dysfunction, fatigue, receipt of opi-
oid analgesics, and pain. No statistically significant differences between breast cancer survivors
and controls were found for cognitive dysfunction and fatal and nonfatal self-harm, although
there was a suggestion of a positive association for the latter. Younger age and less time elapsed
since diagnosis were strongly associated with larger HRs for most outcomes. The relative risks
estimates tended to diminish over time, but anxiety and depression were significantly
increased for 2 and 4 years after breast cancer diagnosis, respectively, while associations for
fatigue, pain, and sleep disorders were elevated for at least 5 to 10 years after diagnosis.
Table 1. (Continued)
Women with history of breast cancer Women with no history of cancer
No. % No. %
Former smoker 16,343 28.39 60,604 26.34
Unknown 1,211 2.10 6,492 2.82
Comorbidities at index date
Diabetes 3,844 6.68 14,030 6.10
History of coronary heart disease or stroke 4,648 8.07 18,523 8.05
Prior history of (>1 year before index date)§
Anxiety 11,986 20.82 45,482 19.77
Depression 16,771 29.13 65,628 28.53
Cognitive dysfunction¥ - - - -
Fatigue 11,200 19.45 42,578 18.51
Sleep disorder 7,221 12.55 27,528 11.97
Opioid prescribing 12,761 22.17 47,765 20.76
Pain 44,752 77.73 173,112 75.24
Sexual dysfunction 1,670 2.90 6,479 2.82
Self-harm 1,652 2.87 6,847 2.98
BMI, body mass index; IMD, Index of Multiple Deprivation.
� Refers to all patients potentially eligible for analyses. The number of patients included in analyses varied by outcome because we excluded women who had that
particular outcome in the year before the index date, as we assumed that these were likely to still be under treatment at the index date.
† Women with no history of cancer were individually matched by age (within a 3-year age range) to women in the exposed group.
‡ For women in the exposed cohort, the index date was the date of their cancer diagnosis. Women in the comparison group were matched to exposed women on age
and primary care practice and took the same index date as their matched case.
§ Refers to women who had the outcome recorded at >1 year before the index date. Women who had the outcome in the year before the index date were excluded from
the cohort.
¥ Patients with a record of cognitive dysfunction at any point prior to the index date were excluded, as changes in cognitive function are often nonreversible.
https://doi.org/10.1371/journal.pmed.1003504.t001
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Table 2. Associations between breast cancer survivorship and adverse mental health outcomes, fatigue, and pain; women diagnosed with breast cancer in the UK
between 1988 and 2018, compared to women who never had cancer.











PY at risk HR 95% CI p-value HR 95% CI p-value
Anxiety 55,616 5,888 288,115 224,138 20,224 1,306,784 1.35 1.31–1.38 p< 0.001 1.33 1.29–1.36 p< 0.001
Depression 54,073 10,175 261,081 216,355 34,558 1,202,647 1.37 1.35–1.40 p< 0.001 1.35 1.32–1.38 p< 0.001
Cognitive dysfunction 56,052 4,368 315,453 224,444 19,845 1,385,179 1.03 1.00–1.06 p = 0.08 1.00 0.97–1.04 p = 0.88
Fatigue 55,911 8,359 280,982 223,506 28,886 1,266,975 1.31 1.28–1.34 p< 0.001 1.28 1.25–1.31 p< 0.001
Pain 38,771 24,522 100,312 162,037 94,171 505,451 1.28 1.26–1.30 p< 0.001 1.22 1.20–1.24 p< 0.001
Sexual dysfunction 57,444 683 325,393 229,577 2,153 1,435,837 1.34 1.24–1.44 p< 0.001 1.27 1.17–1.38 p< 0.001
Sleep disorder 56,210 6,002 290,786 225,583 16,798 1,338,065 1.71 1.66–1.76 p< 0.001 1.68 1.63–1.73 p< 0.001
Opioid analgesics 52,672 17,315 248,654 213,190 44,850 1,181,155 1.94 1.92–1.98 p< 0.001 1.86 1.83–1.90 p< 0.001
Fatal and nonfatal self-harm§ 32,381 157 188,102 130,590 595 827,007 1.16 0.99–1.36 p = 0.07 1.15 0.97–1.36 p = 0.11
95% CI, 95% confidence interval; BMI, body mass index; CPRD, Clinical Practice Research Datalink; HR, hazard ratio; ONS, Office for National Statistics; PY, person-
years.
� Women with a breast cancer diagnosis were matched with women who never had cancer on age (within a 3-year range), primary care practice (proxy of
socioeconomic status), and eligibility for data linkage (to avoid loss of precision in subset analyses). No other variables were adjusted for in these analyses.
† Further adjusted for diabetes, BMI (restricted cubic spline), and smoking and drinking status.
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Fatal and nonfatal self−harm*
Fig 2. Incidence of adverse mental health outcomes, fatigue, and pain in breast cancer survivors and in women who did
not have cancer. Full red line: breast cancer survivors; dashed blue line: women who never had cancer. �Please note the
different scale used in this graph.
https://doi.org/10.1371/journal.pmed.1003504.g002
PLOS MEDICINE Mental health, fatigue and pain in breast cancer survivors



















































































































































































































































































































































































































































































































































































































































































































1.5 1.5 2 3 4
Hazard ratio
Fatal and non−fatal self−harm
Fig 3. Forest plots of the association between breast cancer survivorship and adverse mental health outcomes, fatigue, and pain, stratified by potential effect
modifiers. 95% CI, 95% confidence interval; HR, hazard ratio; IMD, Index of Multiple Deprivation.
https://doi.org/10.1371/journal.pmed.1003504.g003
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Fig 4. Results of sensitivity analyses. Note: Read codes for very specific diagnoses are provided in S1 Codelists. For anxiety, these included, for example, generalised
anxiety disorder and panic, and for depression, major depressive disorder. 95% CI, 95% confidence interval; CPRD, Clinical Practice Research Datalink; HES, Hospital
Episodes Statistics; HR, hazard ratio; IMD, Index of Multiple Deprivation.
https://doi.org/10.1371/journal.pmed.1003504.g004
PLOS MEDICINE Mental health, fatigue and pain in breast cancer survivors
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003504 January 7, 2021 12 / 17
The association between breast cancer survivorship and anxiety and depression in the UK
is consistent with previous studies, although incidences and effect sizes have varied between
studies [5,7,25–28]. Of 60 studies investigating mental health outcomes in female breast cancer
survivors compared to those without cancer included in a recent systematic review [5], only 1
was conducted in the UK [6]. Khan and colleagues [6] reported similar odds of consulting for
depression and anxiety of breast cancer survivors 5 or more years post diagnosis, compared to
the general population. This study builds on this work, analysing data from 1988 to 2018, to
evaluate the risk of not only anxiety and depression, but 7 other mental health–related out-
comes, and investigated associations from as early as the first year after diagnosis. This gener-
ated evidence for outcomes where none existed in the UK (cognitive dysfunction, fatigue,
sexual dysfunction, pain, opioid prescriptions, sleep disorders, and fatal and nonfatal self-
harm) and provided estimates of the risk of anxiety and depression in the early period of can-
cer survivorship.
The higher incidence of anxiety and depression in this study, compared to studies based on
psychiatric assessment [7,28–30], is likely to be explained by less stringent diagnostic criteria
in primary care. HR estimates for anxiety increased over calendar time; the drivers of this
increase are unclear but might include more recording of symptoms in later years [31]. We did
not observe increased associations of anxiety or depression 5 years after breast cancer diagno-
sis, although we cannot rule out that longer-lasting increased risks may apply for some sub-
groups of survivors. Our results for the secondary outcomes were consistent with the limited
previous research available [5], except that we did not find significantly raised associations for
suicide or cognitive dysfunction. The former is likely a power issue: An increased risk of sui-
cide has been demonstrated in a large international study [32], and our point estimates were in
the same direction, but CIs were very wide due to small numbers of events. For cognitive dys-
function, we found no suggestion of an association except in the youngest patients (18 to 34
years), in contrast with other studies that have estimated 13% to 70% of breast cancer patients
to be affected by this outcome within 2 years of treatment [33]. However, this often involved
mild memory impairments, which may cause distress but usually do not completely impede
most daily activities [34], and it is possible that patients do not report this to their GPs, explain-
ing the lack of effect in our data. In addition, memory problems are not uncommon later in
life, and GPs may not record these concerns as much as for younger women.
A major strength of our study is its population-based nature; we used primary care data
and registration with a primary care practice is nearly universal in the UK [35], so our findings
are likely to be generalisable to the broad population of breast cancer survivors in the UK and
similar settings. CPRD GOLD primary care data have been shown to have good validity for
both cancer and mental health outcomes [36,37]. Confounding by age and socioeconomic sta-
tus was controlled for through matching for narrow age groups and patients’ GP practice; the
latter also had the advantage of accounting for practice-level characteristics that are difficult to
measure (e.g., shared environment). The large study size and the breadth of data available in the
CPRD GOLD primary care database permitted the study of several outcomes over 31 years with
sufficient power to detect small effects and to generate evidence for little studied outcomes such
as sleep disorders. We carried out multiple sensitivity analyses to check the robustness of our
results. However, our study also has some limitations. There may have been detection bias if
breast cancer survivors had more regular contact with health services, even if we expected this
to have little impact as the sensitivity analysis including only patients who consulted in the year
before index showed similar results. There is a potential for misclassification of outcomes due to
incomplete information registered in the primary care record, for example, due to secondary
care diagnoses not being fed back to the GP. There may have been residual confounding: Area-
based deprivation was used as a proxy for socioeconomic status, but this may not accurately
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represent the individual socioeconomic situation; smoking and alcohol data relied on patients
self-reporting accurately to their GP, and no detail on quantity of smoking/drinking was avail-
able; and we had no data on menopausal status, physical activity, or mammography screening,
although age matching should to some extent have taken account of menopausal status. We did
not have data on cancer stage and treatment to allow stratification by these factors.
The results of this study can be used to inform clinical practice. Patient prehabilitation and
rehabilitation strategies often focus on the physical consequences of the disease and treatments
[38,39]. In 2018, a survey of 2,862 women with breast cancer in England revealed that 84%
were not provided with information about the potential negative effect of the cancer on their
long-term mental health, and 75% felt more socially isolated at the end of treatment than at
diagnosis [40]. Talking about common emotional challenges experienced by other patients
may help women to understand better their own emotional journey, reduce stigma, and
encourage patients to raise concerns about their mental health should they need. Increased
awareness is also needed among healthcare professionals to improve detection of the mental
health conditions and may help communication between patients and clinicians, particularly
about sex-related issues, which appears to be poor [41].
Further research is needed to investigate the precise drivers of the associations we have observed
between breast cancer survivorship and adverse mental health outcomes, which may include type
of surgery, receipt and type of systemic treatment, tumour characteristics, presence of lymph-
edema, and other physical sequelae, among others. The effect of age on the likelihood of having
cognitive dysfunction recorded in the clinical record also deserves further attention to ascertain
whether this reflects differential recording by GPs. Interventions to identify, prevent, and treat
mental health conditions in breast cancer survivors need to be designed and tested in robust trials.
There is an important gap in evidence regarding effective treatment strategies for fatigue, sexual
dysfunction, and cognitive dysfunction, all of which may negatively affect quality of life [42].
In conclusion, in this population-based study, we found that breast cancer survivorship was
associated with increased anxiety, depression, sexual dysfunction, and sleep disorder, as well as
fatigue, pain, and being prescribed opioid analgesics, compared to women with no history of
cancer. Incidence of these disorders was particularly elevated in women within the first few
years of breast cancer survivorship and more pronounced in younger women. Increased
fatigue and pain were found for at least 5 to 10 years post-diagnosis. It is imperative to raise
awareness among patients, healthcare professionals, and policy makers about the mental
health needs of the growing population of breast cancer survivors.
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